Residual cardiovascular risk: management beyond statins

  • Jane Armitage is Professor of Clinical Trials and Epidemiology and Honorary Consultant in Public Health Medicine at the University of Oxford.  She joined the Clinical Trial Service Unit (CTSU) in 1990 from a background in clinical medicine, with particular experience in respiratory medicine, geriatrics and diabetes. She has coordinated a series of large-scale clinical trials of therapeutic modulation of atherogenic dyslipidaemia in people with or at risk of vascular disease including the MRC/BHF Heart Protection Study, SEARCH and HPS2-THRIVE, as well as the ASCEND trial of aspirin and fish oils in diabetes.  Her main research interests are in lipoproteins and cardiovascular epidemiology.

  • EAS Snapshots
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Statins represent the cornerstone for lowering low-density lipoprotein cholesterol (LDL-C) to prevent cardiovascular disease (CVD). However, it is clear that even with potent statin therapy, a high risk of CVD events persists, especially in individuals with cardiometabolic disease.

Other lipids ...